Clinical Trials | June 23, 2026
Pfizer lung cancer drug misses key survival goal in Phase 3 trial
The company said the safety profile remained consistent with earlier studies and was considered manageable
The company said the safety profile remained consistent with earlier studies and was considered manageable
New digital platform provides global sponsors with live visibility into R&D, process development and GMP manufacturing operations, enhancing collaboration and decision-making
After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
The company reported consolidated revenue of Rs. 172.9 crore and EBITDA of Rs 25.9 crore in FY26
Advanced comprehensive oncology centre was inaugurated by the legendary former Indian cricketer VVS Laxman
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
Social media emerges as the primary channel for health-related scams, while influencer endorsements and AI-generated content amplify risks for consumers
The research underscores growing concern that the intersection of neurodevelopmental conditions and social disadvantage can significantly compound health risks across the life course
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
